Evommune has two autoimmune disorder treatments with blockbuster potential.

Over the trailing-12-month period, shares of French biotech Abivax (NASDAQ: ABVX) have skyrocketed by a little over 1,000%.

Genomics has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 39.8% ...

Cathie Wood’s ARK ETF published their daily trades for Thursday, March 19, 2026, showcasing a strategic focus on the genomics sector. The largest transaction of the day involved the purchase of 92,140 ...

SoundHound AI (SOUN 2.57%) is a fairly popular artificial intelligence (AI) investment option despite its small size. However ...

Nebius is acquiring more power and has an impressive software stack that helps it stand out from other neocloud providers. The company earned $1.25 billion in annual recurring revenue in 2025 and is ...

Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Reiterates Demand for Full Disclosure of Potential 10X Group – Including Identity of "Certain Members of 10X BNB Cayman Sponsor and Third-Parties" Believes a Board that Cannot Ensure Basic Section 16 ...

Comparing the company's deal with the government alongside MP Materials' deal reveals a lot about its investment proposition.